All In Biotech

Drug Trial Radar · NCT06819215

Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors

Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Preliminary Efficacy of VB15010 Tablets In Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Feb 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

188

Planned (sponsor's estimate)

Start

Oct 30, 2024

Primary completion

Dec 30, 2025

Study completion Mar 30, 2026

Sponsor

Sponsor type
Industry
Collaborators
Shandong Cancer Hospital and Institute
First posted
Feb 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research is designed to determine if experimental treatment with PARP1 inhibitor, VB15010 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

Conditions

  • Cancer
  • Neoplasms
  • Neoplasms, Breast
  • Tumor
  • PARP
  • Ovarian Neoplasms
  • Prostatic Cancer
  • Pancreatic Cancer
  • Breast Cancer
  • Biliary Cancer
  • Colorectal Cancer

Interventions

  • VB15010Drug

    Oral PARP1 inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number of subjects with adverse events/serious adverse eventsTime frame: From time of Informed Consent to 30+7 days post last dose
  2. The number of subjects with dose-limiting toxicity (DLT), as defined in the protocol.Time frame: At the end of Cycle 1(each cycle is 28 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital of Shandong First Medical university

    Jinan, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.